Celularity gets 361 nod from FDA for its amniotic derived wound care products, Natalin and Acelagraft™
Celularity Inc. (Nasdaq: CELU), a regenerative and cellular medicine company, announced that it received recommendation letters from the FDA's Tissue Reference Group (TRG), regarding its Natalin and Acelagraft™ products confirming that each product “appears...
